Motc 40mg we yu de yuz

▎ Motc Struktrɔ

▎ Motc Risach

Wetin na di risach bakgrɔn fɔ Motc?

di maytochכndria dεm we de wok lεk di 'pawa haus' fכ di sεl dεm, de ple imכtant rol fכ mεnten di sεl homכstasis. di kכmyunikeshn mεkanism bitwin di maytochכndria εn di nyuklios dεn bin de fכs fכ lכng tεm fכ sayɛns risεch. di maytochכndria dεm gεt wan indipεndεnt jεnom. biyכn di klas 37 jin dεm, stכdi dεm we dεn jכs du dεn sho se di maytochכndrial DNA de kכd bak bayolojikal aktv sכt pεptida dεm, wan pan dεm na di mitochondrial-dεriv pεptida Motc, we di maytochondrial 12S rRNA rijyכn de kכd. dis diskכvri de sכmtεm εkspεnd di skop fכ di maytochכndrial jεnεtiks, we de gi wan nכvel pεspεktiv fכ elucidate krεs bayolojikal prכsεs dεm lεk mitochondrial-nyukliar kכmyunikeshn εn mεtabolik rεguleshכn.

Naw, tritmɛnt fɔ bɔku bɔku chalenj sik dɛm lɛk mɛtabolism ɛn kronik ɛpatitis B de gɛt bɔku bɔtulnɛk dɛm. di prominεnt rol we Motc de ple fכ skel mכsul mεtabolik rεguleshכn, lεk fכ εnhans glukכs mεtabolism, de sho se i pכtεnshal fכ trit mεtabolik dizכrd. pan tap dat, di abnכmal Motc lεvεl dεm we dεn si na difrεn sik prכsεs dεm dכn mek risechכr dεm fכ invεstigat in rol fכ di sik bigin, fכ go bifo, εn tritmεnt, fכ sכk nyu we fכ כvakom dεn kכndishכn dεm ya we dεn nכ kin trit.

Wetin na di mɛkanism fɔ akshɔn fɔ Motc?

Rεgulεt Mεtabolism-Rεlatεd Sayn Pathways

aktibכt di AICAR-AMPK Sayn Pathway: Motc de aktibכt di AICAR-AMPK signal path bay we i de disrupt di intasεlulyar fכlet-mεtiכnin saykl. aktibכt AMPK de rεgεl di sεlyul εnεji mεtabolism, lεk fכ protεkt glukכs כptek εn fεt asid כksidεshכn. insay glukoz mεtabolism, i de inkrεs di translokeshכn fכ di glukכs transpכrta GLUT4 to di sεl mεmbran, we de mek di sεl glukכs כptek kεpasiti, impruv insulin rεsistεns, εn i de εp fכ prεvεnshכn εn trit mεtabolik sik dεm lεk tayp 2 mεtabolism ^[1]..

ifekt pan כda Pathway dεm: biyכn di AMPK path, Motc de akt bak pan di AKT path, oksidativ strεs path, εn inflameshכn-rεlatεd path. fכ di AKT path, i kin infכlכw sεlyul prכsεs dεm lεk growth, proliferashכn, εn sכvayv bay we i de rεgεl di path in aktiviti. insay di oksidativ strεs path, Motc de ridyus di intasεlulyar oksidativ strεs lεvεl, i de dכn di riaktiv כksijεn spεs (ROS) prodakshכn, εn i de protεkt sεl dεm frכm oksidativ damej. insay inflameshn-rilayt path dεm, i de sכpres di rilis fכ inflammatory mεdiate dεm εn i de εliviet inflammatory rεspכns dεm. fכ egzampl, insay inflammatory pen mכdel dεm, Motc de ridyus inflammatory mεdiεta rilis na di dכsal hכn na di spεnal kכd, we de mek di pen simptom dεm impruv ^[2]..

Figure 1 di praymar fysiolojikal wok dεm we Motc de du inklud fכ ridyus insulin rεsistεns, fכ mek i nכ fat, fכ impruv di mכsul dεm fכ wok, fכ mek di bon mεtabolism, fכ mek di imyun rεgεlεshכn, εn fכ delay di ol ^[1]..

Rɛgyuleshɔn fɔ di Jin Ɛksprɛshɔn

nyuklia jin εksprεshכn rεgulεshכn: we sεl dεm mit mεtabolik strεs, lεk glukכs rεstrikshכn εn כksidεtiv strεs, Motc de transloket to di nyuklios fכ rεgεl di adaptiv nyuklia jin εksprεshכn dεm dεn wan, we de protεkt intasεlulyar homכstasis. fכ egzampl, Motc de mכdulet di εksprεshכn fכ mεtabolism-rεlatεd jin dεm lεk GLUT4, STAT3, εn IL-10, we de infכlכw fysiolojikal prכsεs dεm inklud glukכs mεtabolism εn imyun rεguleshכn. inkrεs GLUT4 εksprεshכn de εnhans sεlyul glukכs כptek; STAT3 de tek pat pan sεl proliferashכn, difrεns, εn imyun rεguleshכn; IL-10, we na anti-inflammatory cytokine, de ridyus inflammatory rispכns we in εksprεshכn de εlevεt ^[1,3]..

Ɛnjɔy Ɛnaji Mɛtabolism

εnhans Glycolysis: Insay difrεn sik mכdel dεm, lεk di lכng ischemia-riperfyushכn injuri (LIRI) mכdel we dεn indyuz bay kadyopulmonary bypass (CPB), Motc prεtritmεnt de εnhans glycolytic flux in pulmonary microvascular endothelial cells (PMVECs). i de mitigate LIRI injuri bay we i de rεstכr sεlyul εnεji homכstasis εn ridyus lipid pεrכksidεshכn tru upregulate di ki glycolytic εnzym PFKFB3. dis de sho se Motc de mכdulet di glycolytic path fכ saplae inof enεji fכ sεl dεm we de כnda strεs, we de mek i de mεnten nכmal sεlyul fכnshכn ^[4]..

Ifɛkt dɛn we di sɛlular protɛkshɔn kin gɛt

Mitigashכn fכ Maytochondrial Damej: Insay wan rεdyushכn nyumonitis (RP) mכdel, Motc sכmtεm ridyus di lכng tisu injuri, inflameshn, εn כksidεtiv strεs we i de rivεs alvεolar εpitεlial sεl apoptosis εn maytochondrial dεmεj. dis mεkanism involv fכ inkrεs nyuklia fכktכ E2-rεlatεd fכktכ 2 (Nrf2) lεvεl dεm εn fכ protεkt in nyuklia translכkeshכn. Nrf2 de aktibכt wan siriכs antioksidant εn sεl-protεktiv jin dεm, we de sef di maytochכndrial fכnshכn. dis de sho se Motc de protεkt di tisu dεm we dεn dכn pwεl bay we i de kip di maytochכndria dεm εn i de ridyus di apoptosis ^{[5] .}.

Protekshכn fכ כda sεl dεm: insay stכdi dεm pan Duchenne mכskul dεstrofi (DMD), dεn fכnshכn se Motc gεt intrinsik mכsul-tכgεt prכpati dεm. i de εnhans glycolytic flux εn enεji prodakshכn kapasiti insay distrofik mכsul dεm, we de kכntribyut fכ impruv mכsul fכnshכn. fכ tכk di tru, in inflammatory pen mכdel dεm, Motc we dεn administret sεntri כ pεrifεral de εliviet pen haypasεnsitiviti bay we i de sכpres inflammatory rεspכns dεm εn nyuronal haypa εksitabiliti, we de gi nyuroprotεktiv ifekt dεm ^[2,6]..

Wetin na di aplikeshɔn dɛn fɔ Motc?

Tritmɛnt fɔ Mɛtabolik Disɔda:

fכ impruv insulin rεsistεns εn fכ mek di mεtabolism nכ de: Motc de εnhans insulin rεsistεns, we rili imכtant fכ mek di tayp 2 mεtabolism nכ de. di insulin rεsistεns na di kכl tin we de mek di tayp 2 mεtabolism bigin. Motc kin impruv insulin sεnsitiviti bay we i de aktibכt di AICAR-AMPK signal path εn rεgεl di intasεlulyar fכlet-mεtiכnin saykl. Risach we Gao Y du sho se i de mek di skel mכsul glukכs tek εn yutilizeshכn, we lεk fכ opin כda glukכs absכpshכn path dεm na sεl dεm, we de mek di bכdi glukכs lεvεl dכn ^[1]..

fכ rεgεl di lipid mεtabolism εn fכ kכmbat di fat: we i kam pan di lipid mεtabolism, Motc de inkrεs di brawn fεt tεmכjεnεsis εn i de mek di wayt fεt brawn. Brawn fεt de it enεji tru tεmכjεnεsis, we di wayt fεt brawn de sho di transfכmeshכn fכ di wayt fεt we de stכr enεji to brawn fεt we de kכnsum enεji. dis prכsεs de εp di bכdi fכ adap to kol εn, mכr imכtant, i de mek i nכ fat εn di lipid mεtabolism dizכrd dεm, we de gi nyu tin dεm fכ mek i nכ fat εn trit am ^[1]..

Fɔ protɛkt ɛn Trit di sik dɛn we gɛt fɔ du wit di mɔsul dɛn:

di prכmot mכsul difrεns: in vitro stכdi dεm sho se wayl-tayp Motc pεptida de εnhans myotubular fכmeshכn insay hכman (LHCN-M2) εn maws (C2C12) mכsul progenitor sεl dεm, we di Y8F mutant pεptida nכ gεt dis ifekt. fכda stכdi dεm sho se Motc de εnhans myotubulogenesis bay we i de intarakt wit di IL-6/Janus kinase/signal transducer εn aktibכt fכ transkripshכn 3 (STAT3) path, we de ridyus STAT3 transkripshכnal aktiviti ^[7]..

Prεvεnshכn fכ di mכsul atrofi: di plasma Motc lεvεl dεm nεgεtiv kכrεlat wit di myostatin lεvεl dεm. Motc de mek di palmitate-induced myotube atrophy in difrεnt C2C12 sεl dεm εn i de ridyus di plasma myostatin lεvεl dεm na di it-induced obese mice. i de mek di mכsul dεm atrofi bay we i de εnhans AKT fכsfכrayleshכn, i de inhεbit di aktvכti fכ FOXO1—we na כpstrim transkripshכn fכktכ fכ myostatin εn כda mכsul-atrofi jin dεm—we i de rεgεl mTORC2 εn PTEN aktiviti εn i de inkrεs di CK2 aktiviti fכ sכpres PTEN ^[8]..

Anti-aging ifekt dεm: Motc εksprεshכn chenj dεm de kכlכs fכ ol, εn i de sho anti-aging prכpati dεm. dis de apin tru mכltipכl mεkanism dεm, we inklud fכ impruv glukכs εn lipid mεtabolism, εnhans sεlyul maytochכndrial fכnshכn, εn ridyus sistεmik krכnik inflameshn. Risach we Gao Y ɛn ɔda pipul dɛn du. i sho se di mεtabolism we de impruv de gi di sεl dεm mכr bכku εn stebul enεji saplai. fכ εnhans di maytochכndrial fכnshכn de lεk fכ כpgrεd di sεl in 'εnεji fכktכri,' we fכ ridyus di inflammatory rεspכns dεm de minimiz inflammatory damej to sεl dεm ^{[1] .}.

Dɔn

as di mitochondrial-derived peptide, Motc de aktibכt signal path dεm lεk AMPK fכ rεgεl glukכs εn lipid mεtabolism, protεkt wayt-to-brawn fεt kכnvכshכn, εn impruv insulin rεsistεns εn fεt, we de gi nכvel tεrapi dεyshכn fכ mεtabolik dizכrd. i de mek di osteoblast difrεns bכku, i de sכpres di osteoclast fכmeshכn, i de bεlε di bon mεtabolism, εn i de sכpכt di skel hεlth mεntenans. i de rεgεl di mכsul dεm difrεns εn i de mek atrofi, i de hכl pכtεnshal fכ intavεnshכn insay di mכsul-rεlatεd dizכrd dεm. Motc de sho strכng εksεsayz-rεlatεd asosieshכn dεm: εksεsayz de upregulate in εksprεshכn, εn i de mεdiet εksεsayz-indyus hεlth bεnεfit dεm. Motc de ple rol bak fכ delay ol pipul dεm εn di prכsεs dεm we de apin wit am.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Ning Ran na wan risachman we gɛt fɔ du wit di Carlson Kɔlej fɔ Veterinari Mɛdisin na Ɔrigon Stet Yunivasiti. In akademik wok de span mɔlikul bayoloji ɛn transleshɔnal mɛdisin, wit fɔs pan tritmɛnt strateji fɔ nyuromɔskular sik dɛm. Ran dɔn kɔ-ɔda bɔku pɔblikeshɔn dɛn na jɔnal dɛn we dɛn kɔmpin dɛn dɔn rivyu, we dɔn kɔntribyut fɔ ɔndastand mɔlikul intavɛnshɔn dɛn na di sik mɔdel dɛn. in risach intres dεm inklud di divεlכpmεnt εn aplikεshכn fכ pεptida-kכnjugεt כligonuklεotayd dεm, εn bak fכ εksplכr di tεrapi pכtεnshal fכ di pεptida dεm we kכmכt na di maytochכndrial. Ning Ran de na di list insay di rɛfrɛns fɔ saytayshɔn [6].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Gao Y, Wei X, Wei P, ɛn ɔda pipul dɛn. Motc Fכnshכnal Prεvεnt Mεtabolik Dizכrd. Mεtabolayt dεm 2023; 13(1).DOI: 10.3390/mɛtabo13010125. Di wan dɛn we de wok fɔ di kɔmni.

[2] Wang Z, Yang L, Xu L, Liao J, Lu P, Jiang J. Sεntri εn pεrifεral mεkanism fכ Motc de atεnuet pen haypasεnsitiviti in wan mays mכdel fכ inflammatory pen. Nyurolɔjik Risach 2024; 46 (2): 165-177.DOI: 10.1080/01616412.2023.2258584.

[3] Benayoun BA, Lee C. Motc: Wan Maytokɔndrial-Ɛnkɔd Rɛgyulatɔ fɔ di Nyukliɔs. Bayoɛsay dɛn 2019; 41(9): e1900046.DOI: 10.1002/bies.201900046.

[4] Shen Z, Lu P, Jin W, ɛn ɔda pipul dɛn. Motc de Promot Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway fכ Ameliorate CPB-indyus Lכng Injuri. Amɛrikan Jɔnal fɔ Rɛspiratɔri Sɛl ɛn Mɔlikul Bayoloji 2025. 10.1165/rcmb.2024-0533OC.

[5] Zhang Y, Huang J, Zhang Y, ɛn ɔda pipul dɛn. di Maytochondrial-Dεrivεd Pεptid Motc de Aliviet Rεdyushכn Nyumonitis via wan Nrf2-Dipεndεnt Mεkanism. Antiɔksidant dɛn 2024; 13. https://api.semanticscholar.org/CorpusID:269876125. Di wan dɛn we de stɔdi bɔt di Baybul.

[6] Ran N, Lin C, Leng L, ɛn ɔda pipul dɛn. Motc de promuot fכsfכrodiamidεt mכfכlino כligomεr כptek εn efikכs in distrofik mays dεm. Embo Mɔlikul Mɛdisin 2021; 13(2): e12993.DOI: 10.15252/emmm.202012993. Di wan dɛn we de wok fɔ di kɔmni.

[7] García-Benlloch S, Revert-Ros F, Blesa JR, Alis R. Motc de promuot mכsul difrεns in vitro. Pɛptid dɛn 2022; 155: 170840.DOI: 10.1016/j.pεptida.2022.170840.

[8] Kumagai H, Coelho A. R., Wan J, ɛn ɔda pipul dɛn. Motc de ridyus myostatin εn mכsul atrofi signal. Amɛrikan Jɔnal fɔ Fisiɔlɔji-Ɛndokrinɔlɔji ɛn Mɛtabolism 2021; 320(4): E680-E690.DOI: 10.1152/ajpendo.00275.2020. Di wan dɛn we de wok fɔ di kɔmni.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto famasitik, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.